Management of Nausea and Vomiting in Elderly Patients

Initial Assessment and Treatment

• The American College of Physicians recommends identifying and treating underlying causes of nausea and vomiting, including medication-induced, gastritis or gastroesophageal reflux, bowel obstruction or severe constipation, metabolic abnormalities, and gastroparesis, with a strength of evidence rated as high 1, 2
• For gastritis or gastroesophageal reflux, the National Comprehensive Cancer Network suggests using proton pump inhibitors or H2 receptor antagonists, with a strength of evidence rated as moderate 2, 3

Pharmacological Treatment

• Dopamine receptor antagonists, such as metoclopramide 5-10 mg PO/IV three times daily, are recommended as first-line treatment for nausea and vomiting with lethargy in elderly patients, with a strength of evidence rated as high 1, 3
• The National Comprehensive Cancer Network recommends using haloperidol 0.5-2 mg PO/IV every 4-6 hours, with a strength of evidence rated as moderate 2, 4
• Olanzapine 2.5-5 mg PO daily may be used, especially in palliative care settings, with a strength of evidence rated as low 2, 3
• For anxiety-related nausea, adding benzodiazepines, such as lorazepam 0.5-1 mg PO/IV every 4-6 hours, may be considered, with a strength of evidence rated as low 4, 5

Second-Line Treatment

• The National Comprehensive Cancer Network suggests adding 5-HT3 receptor antagonists, such as ondansetron 4-8 mg PO/IV 2-3 times daily, for persistent symptoms, with a strength of evidence rated as moderate 2
• Granisetron 1 mg PO twice daily or 34.3 mg transdermal patch weekly may also be used, with a strength of evidence rated as low 3

Management of Lethargy

• Assessing for dehydration and correcting fluid/electrolyte imbalances is crucial, with a strength of evidence rated as high 4
• Reducing doses of medications that may contribute to lethargy and evaluating for underlying causes, such as hypercalcemia, infection, or medication side effects, is recommended, with a strength of evidence rated as moderate 1, 2

Special Considerations

• Using lower starting doses, monitoring for extrapyramidal side effects, and avoiding long-term use of benzodiazepines are important considerations in elderly patients, with a strength of evidence rated as high 1, 3, 5

Refractory Symptoms

• For severe, persistent nausea and vomiting, considering continuous IV or subcutaneous infusion of antiemetics, combination therapy, or cannabinoids, with caution in elderly patients, is recommended, with a strength of evidence rated as low 1, 2
• Palliative sedation may be considered as a last resort for intractable symptoms in end-of-life care, with a strength of evidence rated as low 1, 2

Management of Nausea and Vomiting in Elderly Patients

Initial Assessment and Treatment

• The National Comprehensive Cancer Network recommends starting with reduced doses of medications in elderly patients, such as lorazepam 0.25 mg orally 2-3 times daily, and gradually tapering when discontinuing 6

Pharmacological Treatment Considerations

• Elderly patients are especially sensitive to benzodiazepines and antipsychotics, and should be monitored closely for extrapyramidal side effects, according to the Journal of the National Comprehensive Cancer Network 6
• The American College of Physicians suggests that elderly patients require dose reduction of 25-50% initially when using antiemetics, such as metoclopramide or haloperidol 6

Pharmacologic and Non‑Pharmacologic Management of Anxiety‑Related Vomiting in Older Adults

First‑Line Benzodiazepine Therapy

First‑Line Dopamine Antagonist Therapy

Alternative Routes and Dose Adjustments

Non‑Pharmacologic Support

Advanced Delivery for Refractory Cases

Guideline Summary: Diagnosis and Pharmacologic Management of Nausea and Vomiting in Older Adults

Diagnostic Evaluation

• Medication review – Systematically assess all prescribed and over‑the‑counter drugs for psychoactive agents (e.g., benzodiazepines, corticosteroids, anticholinergics, opioids) that are frequent contributors to nausea in the elderly population. 10
• Red‑flag assessment – Immediate evaluation is required when any of the following occur: vomiting of blood, severe abdominal pain, abrupt onset accompanied by cardiac symptoms, or syncope, as these may signal serious underlying pathology. 11

First‑Line Pharmacologic Therapy

• Metoclopramide – Initiate at the lower adult dose range (5 mg PO/IV three times daily) for older patients; the drug acts on dopaminergic receptors in the chemoreceptor trigger zone and promotes gastric emptying. Dose reduction of 25–50 % compared with standard adult regimens is recommended for this age group. 10

Second‑Line Add‑On Therapy

• Ondansetron – If nausea persists after 24–48 hours of metoclopramide, add a 5‑HT₃ antagonist (4–8 mg PO/IV 2–3 times daily). This provides a complementary mechanism by blocking serotonin receptors involved in emesis. 10

Third‑Line and Cause‑Specific Options

• Dexamethasone – Use 2–8 mg PO/IV 2–3 times daily for nausea associated with bowel obstruction or raised intracranial pressure; corticosteroid therapy can reduce inflammatory and edema‑related triggers. 10
• Octreotide – For malignant bowel obstruction, employ a somatostatin analogue to diminish gastrointestinal secretions and control vomiting; avoid metoclopramide when a complete mechanical obstruction is present. 10

Safety Monitoring and Drug Interactions

• QTc prolongation – Co‑administration of haloperidol (a dopamine antagonist) and ondansetron (a 5‑HT₃ antagonist) can lengthen the QT interval; monitor electrocardiograms and consider alternative agents in patients with baseline cardiac risk. 10

End‑of‑Life and Palliative Considerations

• Palliative sedation – In refractory cases at the end of life, where all other pharmacologic and supportive measures have failed, a carefully titrated sedation regimen may be employed as a last‑resort option to alleviate intractable nausea and vomiting. 10